Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Photo/Multimedia, Contract/Agreement

Selexis and Inotrem Enter Service Agreement to Advance Inotrem's Chronic Inflammatory Disease Program

Selexis SA, a JSR Life Sciences company, and Inotrem SA, an advanced clinical-stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, have signed a service agreement to develop the cell line for Inotrem's antibody-based candidate to address chronic inflammations. Under the agreement terms, Inotrem will leverage Selexis' proprietary SUREtechnology Platformtm, a suite of cell line development technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines.

"The Selexis SUREtechnology Platform has demonstrated value in advancing cell lines for many inflammatory disease therapeutics. In turn, the Selexis team has helped our partners all over the world advance their programs from preclinical development to commercialization," said Sonja Delalu, PhD, Selexis associate director, business development and licensing. "Research around the TREM-1 pathway is promising, and Inotrem's approach to targeting inflammatory diseases is novel and exciting. We look forward to providing the Inotrem team with a robust research cell bank."

TREM-1 (triggering receptor expressed on myeloid cells-1) is an immunoreceptor expressed on innate immune cells. Inotrem is focused on the biology of TREM-1 pathway, an innate immune amplifier, to control innate immunity and restore a balanced response in inflammatory diseases.

"With multiple complex factors to consider, selecting a cell line development partner is an incredibly daunting task. Selexis' reputation for delivering a robust, flexible protein expression platform made our decision a simple one," said Marc Derive, Inotrem's chief scientific officer and co-founder. "From their expert team to their SUREtechnology Platform, Selexis checks all of the boxes for a successful partnership. We are looking forward to working with them during this pivotal time in the development of our new asset that addresses chronic inflammatory conditions."

Selexis' modular SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines, providing seamless integration of the development continuum from discovery to commercialization.

About Selexis SA

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 150 drug candidates in preclinical and clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company's technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

About Inotrem

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, LR12 (nangibotide), with potential applications in a number of critical care therapeutic indications such as septic shock, COVID-19 and myocardial infarction. In parallel, Inotrem has also launched an antibody-based program to develop a new therapeutic modality targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. www.inotrem.com


- Web www.selexis.com 
- LinkedIn www.linkedin.com/company/selexis-sa 
- Twitter www.twitter.com/SelexisSA 
- Facebook www.facebook.com/SelexisSA

These press releases may also interest you

at 19:31
General Dynamics Mission Systems , and Iridium Communications Inc. announced today that they have been awarded a contract by the Space Development Agency in the amount of $324,516,613, including a base amount of $162,954,122 and $161,562,491 in...

at 19:30
The data center infrastructure management (DCIM) solutions market is a part of the global internet services and infrastructure market within the global IT services market. Apart from the market in focus, Technavio's market analysis reports also...

at 19:14
The Surfrider Foundation today released its annual 2021 Clean Water Report to protect public health and clean water for all people. The report highlights Surfrider's Ocean Friendly Gardens program and results from the Blue Water Task Force, the...

at 19:06
Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) in Chicago...

at 19:00
The advanced predictive analytics software market is a part of the global application software market. Apart from the market in focus, Technavio's market analysis reports also provide in-depth coverage of the external factors influencing the parent...

at 19:00
HitPaw, a company aiming to develop the best digital creation solution, today releases the brand new video enhancement software - HitPaw Video Enhancer. HitPaw Video Enhancer is combined with Artificial Intelligence to upscale videos automatically...

News published on 19 january 2022 at 08:35 and distributed by: